{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:07:33Z","timestamp":1795208853441,"version":"4.10.3"},"reference-count":17,"publisher":"Wiley","issue":"6b","license":[{"start":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T00:00:00Z","timestamp":1328572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Study Type \u2013 Prognosis (case series)<\/jats:p>\n                    <jats:p>Level of Evidence\u20034<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What's known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>Adjuvant intravesical BCG therapy is the most effective regimen for non\u2010muscle\u2010invasive bladder cancer. Previously, patients who experienced recurrences after BCG therapy tended to be lumped together as patients with \u2018BCG failure\u2019, but BCG failure was defined inconsistently in each study and several studies indicated that patients with a particular pattern of BCG failure had a worse prognosis.<\/jats:p>\n                    <jats:p>We divided patients with BCG failure into four groups, which were based mainly on the responsiveness to BCG therapy and duration until tumour recurrence. Patients in the BCG\u2010refractory group, in particular, had a higher risk for subsequent stage progression and disease\u2010specific death over a long duration compared with patients in the other BCG\u2010failure groups. As the definitions of BCG failure used to date have been decidedly heterogeneous, we recommend that standardized treatment decisions, protocols and recommendations be established according to individual BCG failure patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>To investigate the differences in the clinical features and subsequent stage progression and disease\u2010specific survival among patients with Bacillus Calmette\u2010Gu\u00e9rin (BCG) failure, after dividing these patients into BCG\u2010refractory, \u2010resistant, \u2010relapsing, and \u2010intolerant groups.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>We identified 173 patients with initial BCG failure from 521 patients who had undergone induction BCG therapy for non\u2010muscle\u2010invasive bladder cancer, excluding CIS, between 1987 and 2009.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Patients were stratified into four BCG\u2010failure groups, and each prognostic outcome was evaluated.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Median follow\u2010up period from initial BCG failure was 4.7 years.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>A total of 42 patients (24.3%) were stratified into the BCG\u2010refractory, three (1.7%) into the BCG\u2010resistant, 106 (61.3%) into the BCG\u2010relapsing, and 22 (12.7%) into the BCG\u2010intolerant group.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Twenty\u2010four patients (13.9%) experienced stage progression during follow\u2010up.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Multivariate analysis showed that pathological G3 at BCG failure (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.014; risk ratio 2.84) and BCG\u2010refractory (\n                            <jats:italic>P<\/jats:italic>\n                            &lt; 0.001; risk ratio 4.68) were independent predictors for stage progression. The 10\u2010year progression\u2010free survival rates were 53.2%, 91.1% and 93.8% in the BCG\u2010refractory, BCG\u2010relapsing and BCG\u2010intolerant groups, respectively. The stage progression rate was higher in the BCG\u2010refractory than in the BCG\u2010relapsing (\n                            <jats:italic>P<\/jats:italic>\n                            &lt; 0.001) and BCG\u2010intolerant (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.007) groups.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Similarly, the 10\u2010year disease\u2010specific survival rate in the BCG\u2010refractory group was significantly worse than those in the other BCG failure groups (\n                            <jats:italic>P<\/jats:italic>\n                            &lt; 0.001).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Stratification of BCG failure into the above\u2010mentioned four groups can identify patients with BCG\u2010failure in terms of their prognosis.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The potential risk for critical adverse events was higher in the BCG\u2010refractory group than in the other BCG\u2010failure groups, despite the fact that patients in each group all underwent induction BCG therapy, therefore, treatment decisions, protocols and recommendations should be established based on each individual BCG\u2010failure pattern.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2011.10894.x","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T08:57:20Z","timestamp":1328605040000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Prognostic significance of Bacillus Calmette\u2010Gu\u00e9rin failure classification in non\u2010muscle\u2010invasive bladder cancer"],"prefix":"10.1111","volume":"110","author":[{"given":"Hiroshi","family":"Shirakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,2,7]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.03.017"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)62377-2"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00212-X"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.12.024"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.10.006"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01603-X"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00116-8"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.09.087"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37317-2"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39547-2"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00510-4"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.2720"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000062605.92268.c6"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.08.066"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2007.11.033"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)40575-1"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04764.x"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2011.10894.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2011.10894.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:31:30Z","timestamp":1761755490000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2011.10894.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,7]]},"references-count":17,"journal-issue":{"issue":"6b","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1111\/j.1464-410X.2011.10894.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2011.10894.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,7]]},"assertion":[{"value":"2012-02-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}